Barry D. Quart
Chief Executive Officer at Heron Therapeutics Inc.
Sits on 3 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 8 years
- Director since
- 2023
8 years of board service in total across 3 boards, counting each seat separately. Longest: Heron Therapeutics Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Kiniksa Pharmaceuticals International plc June 3, 202597.6%
-
Kiniksa Pharmaceuticals International plc June 6, 202397.3%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 19, 2026 | Kiniksa Pharmaceuticals International plc | Gift | −2,600 | — | — |
| May 29, 2026 | Kiniksa Pharmaceuticals International plc | Option exercise | +2,799 | — | — |
| Apr 28, 2026 | Kiniksa Pharmaceuticals International plc | Option exercise | +13,099 | $14.33 | $187,709 |
| Apr 28, 2026 | Kiniksa Pharmaceuticals International plc | Open-market sale | −13,099 | $50.10 | $656,260 |
| Apr 6, 2026 | Kiniksa Pharmaceuticals International plc | Option exercise | +6,901 | $14.33 | $98,891 |
| Apr 6, 2026 | Kiniksa Pharmaceuticals International plc | Open-market sale | −6,901 | $50.00 | $345,050 |
| Feb 12, 2026 | Kiniksa Pharmaceuticals International plc | Option exercise | +2,690 | $15.47 | $41,614 |
| Feb 12, 2026 | Kiniksa Pharmaceuticals International plc | Open-market sale | −2,690 | $45.00 | $121,050 |
| Feb 10, 2026 | Kiniksa Pharmaceuticals International plc | Option exercise | +110 | $15.47 | $1,702 |
| Feb 10, 2026 | Kiniksa Pharmaceuticals International plc | Open-market sale | −110 | $45.00 | $4,950 |
| Feb 4, 2026 | Kiniksa Pharmaceuticals International plc | Option exercise | +2,602 | $15.47 | $40,253 |
| Feb 4, 2026 | Kiniksa Pharmaceuticals International plc | Open-market sale | −2,602 | $45.02 | $117,142 |
| Feb 3, 2026 | Kiniksa Pharmaceuticals International plc | Option exercise | +12,528 | $15.47 | $193,808 |
| Feb 3, 2026 | Kiniksa Pharmaceuticals International plc | Open-market sale | −12,528 | $45.27 | $567,143 |
| Feb 2, 2026 | Kiniksa Pharmaceuticals International plc | Option exercise | +830 | $15.47 | $12,840 |
Questions about Barry D. Quart
What boards is Barry D. Quart on?
Barry D. Quart sits on the boards of Connect Biopharma Holdings Limited, Heron Therapeutics Inc. and Kiniksa Pharmaceuticals International plc.
What company is Barry D. Quart the CEO of?
Barry D. Quart is Chief Executive Officer of Heron Therapeutics Inc. and Barry D. Quart has been Chief Executive Officer of Connect Biopharma Holdings Limited since March 2026.
How long has Barry D. Quart served on boards?
Our records show at least 8 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.